›› 2018, Vol. 38 ›› Issue (7): 801-.doi: 10.3969/j.issn.1674-8115.2018.07.016

• Review • Previous Articles     Next Articles

Progress in 5-HT2C receptor as a therapeutic target for treatment of schizophrenia

WANG Ye-wei, ZHANG Chen   

  1. Biochemical Laboratory, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
  • Online:2018-07-28 Published:2018-07-30
  • Supported by:
    National Natural Science Foundation of China, 81000581, 81471358, 81771450; National Key Clinical Discipline at Shanghai Mental Health Center, OMA-MH 2011-873; Shanghai Science and Technology Development Fund, 12140904200; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Support, 20152530)。

Abstract: With an increasing number of reports on side effects including antipsychotic induced weight gain and cardiovascular risks, interest of the researchers has been transferred to a new target for the treatment of schizophrenia—serotonin 2C receptor (5-HT2C receptor). On one hand, activation on 5-HT2C receptors can lead to decrease of dopamine in the nigrostriatum, which presents its potential antipsychotic effect; on the other hand, the second-generation of antipsychotics’ antagonism on the 5-HT2C receptors is an important factor of patients weight gain. Conversely, agonism on the 5-HT2C receptors may result in weight loss efficacy. This paper introduced the potential therapeutical effect of 5-HT2C receptor on schizophrenia and the relation between the receptor and correlated weight gain.

Key words: serotonin 2Creceptor (5-HT2Creceptor), schizophrenia, antipsychotic induced weight gain, gene polymorphism, vabicaserin

CLC Number: